Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in esophagitis trial

Eupraxia Pharmaceuticals (EPRX) announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. The company’s ongoing RESOLVE trial is evaluating EP-104GI across multiple patient cohorts by assessing key clinical measurements associated with EoE. All three patients reported reduced symptom severity, with peak SDI score reductions of up to 5 points and an average reduction of 46% at 12 weeks. The largest improvement in tissue health observed in any cohort to date, with peak Stage and Grade score reductions of 89% and 88%, respectively, and mean Stage and Grade score reductions of 66% and 65%. Mean 94% reduction in eosinophils across a standard number of biopsy sites within the treated area. There was a mean 62% remission rate across all biopsy sites. Plasma fluticasone levels remained predictable and well below published levels for daily asthma treatments, with no serious adverse events reported. Cohort 7 is fully enrolled, with 12-week data expected in Q2.